Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies

American Journal of Cardiology

Volumn 108, Issue 7, 2011, Pages 905-911

  Wiviott, Stephen D ^a   Desai, Nihar ^a   Murphy, Sabina A ^a   Musumeci, Guiseppe ^b   Ragosta, Michael ^c   Antman, Elliott M ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CONTROLLED STUDY; DEATH; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; ITALY; MALE; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TREATMENT OUTCOME; UNITED STATES;

EID: 80052741598     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.05.020     Document Type: Article

References (19)

1. J.A. Jakubowski, K.J. Winters, H. Naganuma, and L. Wallentin Prasugrel: a novel thienopyridine antiplatelet agent A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile Cardiovasc Drug Rev 25 2007 357 374 (Pubitemid 350233359)
2. S.D. Wiviott, D. Trenk, A.L. Frelinger, M. O'Donoghue, F.J. Neumann, A.D. Michelson, D.J. Angiolillo, H. Hod, G. Montalescot, D.L. Miller, J.A. Jakubowski, R. Cairns, S.A. Murphy, C.H. McCabe, E.M. Antman, E. Braunwald PRINCIPLE-TIMI 44 Investigators Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and AggregationThrombolysis In Myocardial Infarction 44 trial Circulation 116 2007 2923 2932 (Pubitemid 350291199)
3. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.J. Neumann, D. Ardissino, S. De Servi, S.A. Murphy, J. Riesmeyer, G. Weerakkody, C.M. Gibson, and E.M. Antman Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
4. E.F. Unger Weighing benefits and risksthe FDA's review of prasugrel N Engl J Med 361 2009 942 945
5. United States Food and Drug Administration FDA approved drug products http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.DrugDetails 2009 Accessed on May 9, 2011
6. R.E. Wrishko, C.S. Ernest, D.S. Small, Y.G. Li, G.J. Weerakkody, J.R. Riesmeyer, W.L. Macias, S. Rohatagi, D.E. Salazar, E.M. Antman, S.D. Wiviott, E. Braunwald, and L. Ni Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 J Clin Pharmacol 49 2009 984 998
7. S.D. Wiviott, E.M. Antman, and E. Braunwald Prasugrel Circulation 122 2010 394 403
8. S.D. Wiviott, E.M. Antman, C.M. Gibson, G. Montalescot, J. Riesmeyer, G. Weerakkody, K.J. Winters, J.W. Warmke, C.H. McCabe, E. Braunwald TRITON-TIMI 38 Investigators Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) Am Heart J 152 2006 627 635 (Pubitemid 44396884)
9. N. Desai, E. Antman, and S. Murphy Lack of benefit and evidence for harm with prasugrel as compared to clopidogrel in patients with a history of TIA/CVA undergoing PCI: insights from TRITON-TIMI 38 ACC scientific sessions abstract 2009
10. H.C. Diener, J. Bogousslavsky, L.M. Brass, C. Cimminiello, L. Csiba, M. Kaste, D. Leys, J. Matias-Guiu, H.J. Rupprecht MATCH Investigators Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
11. R.L. Sacco, H.C. Diener, S. Yusuf, D. Cotton, S. Ounpuu, W.A. Lawton, Y. Palesch, R.H. Martin, G.W. Albers, P. Bath, N. Bornstein, B.P. Chan, S.T. Chen, L. Cunha, B. Dahlöf, J. De Keyser, G.A. Donnan, C. Estol, P. Gorelick, V. Gu, K. Hermansson, L. Hilbrich, M. Kaste, C. Lu, T. Machnig, P. Pais, R. Roberts, V. Skvortsova, P. Teal, D. Toni, C. Vandermaelen, T. Voigt, M. Weber, B.W. Yoon PRoFESS Study Group Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke N Engl J Med 359 2008 1238 1251
12. S.D. Wiviott, E. Braunwald, C.H. McCabe, I. Horvath, M. Keltai, J.P. Herrman, F. Van de Werf, W.E. Downey, B.M. Scirica, S.A. Murphy, E.M. Antman TRITON-TIMI 38 Investigators Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial Lancet 371 2008 1353 1363
13. M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser, P. Rickenbacher, P. Hunziker, C. Mueller, R. Jeger, F. Bader, S. Osswald, C. Kaiser BASKET-LATE Investigators Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591 (Pubitemid 44881238)
14. J. Daemen, P. Wenaweser, K. Tsuchida, L. Abrecht, S. Vaina, C. Morger, N. Kukreja, P. Jni, G. Sianos, G. Hellige, R.T. van Domburg, O.M. Hess, E. Boersma, B. Meier, S. Windecker, and P.W. Serruys Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
15. P. Wenaweser, J. Dörffler-Melly, K. Imboden, S. Windecker, M. Togni, B. Meier, A. Haeberli, and O.M. Hess Stent thrombosis is associated with an impaired response to antiplatelet therapy J Am Coll Cardiol 45 2005 1748 1752 (Pubitemid 40779850)
16. P. Buonamici, R. Marcucci, A. Migliorini, G.F. Gensini, A. Santini, R. Paniccia, G. Moschi, A.M. Gori, R. Abbate, and D. Antoniucci Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317 (Pubitemid 46891710)
17. D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dörrler, T. Morath, A. Schömig, A. Kastrati, and N. von Beckerath Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
18. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano, and G. Montalescot Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
19. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, J.T. Brandt, J.R. Walker, E.M. Antman, W. Macias, E. Braunwald, and M.S. Sabatine Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362